Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
Price : $35 *
At a glance
- Drugs Defactinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Verastem; Verastem Oncology
- 31 Aug 2018 Biomarkers information updated
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 24 Jan 2017 Status changed from active, no longer recruiting to completed.